Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TET2 antisense RNA 1 (TET2-AS1) is a long noncoding RNA gene transcribed antisense to the TET2 locus[7]. Antisense RNAs, including TET2-AS1, typically regulate gene expression through epigenetic, transcriptional, or post-transcriptional mechanisms, often by interfering with the transcription, stability, or translation of their sense gene partners[3]. While many antisense lncRNAs have roles in cancer, immunity, and development, specific biological and disease functions of TET2-AS1 remain under-explored. TET2-AS1 belongs to the class of antisense lncRNAs and is not an enzyme, receptor, or ion channel. It may have regulatory functions impacting TET2 itself and potentially influence disease states, such as immunodeficiency[7]. No drugs are currently known to interact with TET2-AS1, and no safety concerns have been reported for this molecule in a therapeutic context. If more detailed disease, interaction, or biomarker data become available, new entries may be needed, but the above reflects the current state of knowledge.
Not applicable, as there are no drugs targeting TET2-AS1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TET2 antisense RNA 1 (TET2-AS1).